Emerging Drug Developer: Itero Biopharmaceuticals

Itero Biopharmaceuticals

The executive team behind the Itero start-up says that high-tech companies can teach biotech a thing or two about more efficient drug development. Specifically, signing up partnership agreements with companies halfway around the world can help move product work, especially when you're out to penetrate the world of biosimilars. There's a lot that Itero won't discuss at this stage, but development strategy is taking center stage. Article

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.